Advancing breakthroughs for patients who need them most

Advancing breakthroughs for patients who need
them most

Because patients deserve better options — and better outcomes.

Many solid tumors are difficult to treat due to dense fibrotic tumor microenvironments that impede the immune system and protect tumor cells.

OmniNano Pharmaceuticals is developing dual mechanism nanomedicines, engineered to synergistically target tumor cells and the tumor microenvironment.

Introducing ONP-001: A Dual-Mechanism micelle designed to Remodel the Tumor and Deliver Chemotherapy More Effectively

Targeting the Root Causes of Treatment Failure

  • Pancreatic tumor cells are embedded in a dense, fibrotic tumor microenvironment (the desmoplastic stroma) that limits immune infiltration and prevents therapies from reaching the tumor's core.

  • Most treatments target cancer cells but fail to address these barriers - the key drivers of resistance and poor clinical outcomes.

  • Patients with pancreatic cancer urgently need therapies that target the root causes of treatment failure, not just stronger chemotherapy.

  • ONP-001 doesn't just deliver drugs - it remodels the tumor microenvironment enabling therapies to work better.

  • This fundamental shift is what makes ONP-001 uniquely capable of changing treatment outcomes in pancreatic cancer.

Before ONP-001:

A Dense, Impenetrable Tumor Microenvironment

Pancreatic tumors are reinforced by a rigid, fibrotic stroma that blocks drug penetration, protects cancer stem cells and drives treatment resistance.

After ONP-001:

A Remodeled, Accessible, and Vulnerable Tumor

ONP-001 co-delivers chemotherapy and a stroma-modulating agent in a single nanocarrier - reducing fibrosis, normalizing vasculature, relieving hypoxia, depleting cancer stem cells and killing cancer cells with localized chemotherapy.

ONP-001 transforms one of the most treatment-resistant cancers into a tumor that therapies can finally reach - and destroy.